Biomarker for diagnosis and prognosis of prostate cancer and application of biomarker

The invention relates to the technical field of biological medicine, in particular to a biomarker for diagnosis and prognosis of prostatic cancer and application of the biomarker. More specifically, the invention relates to a biomarker for diagnosis and prognosis of prostate cancer, and the biomarke...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ZHANG KAISHAN, HUANG CHENG, RAO LANGQING, YU LEI, MA NING, TIAN HUA
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ZHANG KAISHAN
HUANG CHENG
RAO LANGQING
YU LEI
MA NING
TIAN HUA
description The invention relates to the technical field of biological medicine, in particular to a biomarker for diagnosis and prognosis of prostatic cancer and application of the biomarker. More specifically, the invention relates to a biomarker for diagnosis and prognosis of prostate cancer, and the biomarker is DHFRL1 and/or TMEM87A. The inventor has found that the expression level of DHFRL1 and TMEM87A in prostate cancer patients is obviously higher than that in healthy people. More particularly, the inventor finds that high-level expression of DHFRL1 and/or TMEM87A has good sensitivity and specificity when being used for diagnosing prostatic cancer and is related to prognosis of prostatic cancer patients, so that DHFRL1 and/or TMEM87A can be used as a biomarker for diagnosis and prognosis judgment of prostatic cancer. 本发明涉及生物医药技术领域,特别是涉及一种用于前列腺癌诊断和预后判断的生物标志物及其应用。更具体地,本发明涉及一种用于前列腺癌的诊断和预后判断的生物标志物,所述生物标志物是DHFRL1和/或TMEM87A。本发明人已发现,DHFRL1和TMEM87A在前列腺癌患者中的表达水平明显高于健康人群中的表达水平。更特别地,本发明人发现,DHFRL1和/或TMEM87A的高水平表达在用于诊断前列腺癌时具有良
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN117625790A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN117625790A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN117625790A3</originalsourceid><addsrcrecordid>eNrjZAh1yszPTSzKTi1SSMsvUkjJTEzPyy_OLFZIzEtRKCjKh_Ly00Cc4pLEklSF5MS8ZKBykILEgoKczOTEksz8PJCSJJhZPAysaYk5xam8UJqbQdHNNcTZQze1ID8-tbggMTk1L7Uk3tnP0NDczMjU3NLA0ZgYNQD1wTlu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Biomarker for diagnosis and prognosis of prostate cancer and application of biomarker</title><source>esp@cenet</source><creator>ZHANG KAISHAN ; HUANG CHENG ; RAO LANGQING ; YU LEI ; MA NING ; TIAN HUA</creator><creatorcontrib>ZHANG KAISHAN ; HUANG CHENG ; RAO LANGQING ; YU LEI ; MA NING ; TIAN HUA</creatorcontrib><description>The invention relates to the technical field of biological medicine, in particular to a biomarker for diagnosis and prognosis of prostatic cancer and application of the biomarker. More specifically, the invention relates to a biomarker for diagnosis and prognosis of prostate cancer, and the biomarker is DHFRL1 and/or TMEM87A. The inventor has found that the expression level of DHFRL1 and TMEM87A in prostate cancer patients is obviously higher than that in healthy people. More particularly, the inventor finds that high-level expression of DHFRL1 and/or TMEM87A has good sensitivity and specificity when being used for diagnosing prostatic cancer and is related to prognosis of prostatic cancer patients, so that DHFRL1 and/or TMEM87A can be used as a biomarker for diagnosis and prognosis judgment of prostatic cancer. 本发明涉及生物医药技术领域,特别是涉及一种用于前列腺癌诊断和预后判断的生物标志物及其应用。更具体地,本发明涉及一种用于前列腺癌的诊断和预后判断的生物标志物,所述生物标志物是DHFRL1和/或TMEM87A。本发明人已发现,DHFRL1和TMEM87A在前列腺癌患者中的表达水平明显高于健康人群中的表达水平。更特别地,本发明人发现,DHFRL1和/或TMEM87A的高水平表达在用于诊断前列腺癌时具有良</description><language>chi ; eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PHYSICS ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; TESTING ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240301&amp;DB=EPODOC&amp;CC=CN&amp;NR=117625790A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240301&amp;DB=EPODOC&amp;CC=CN&amp;NR=117625790A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHANG KAISHAN</creatorcontrib><creatorcontrib>HUANG CHENG</creatorcontrib><creatorcontrib>RAO LANGQING</creatorcontrib><creatorcontrib>YU LEI</creatorcontrib><creatorcontrib>MA NING</creatorcontrib><creatorcontrib>TIAN HUA</creatorcontrib><title>Biomarker for diagnosis and prognosis of prostate cancer and application of biomarker</title><description>The invention relates to the technical field of biological medicine, in particular to a biomarker for diagnosis and prognosis of prostatic cancer and application of the biomarker. More specifically, the invention relates to a biomarker for diagnosis and prognosis of prostate cancer, and the biomarker is DHFRL1 and/or TMEM87A. The inventor has found that the expression level of DHFRL1 and TMEM87A in prostate cancer patients is obviously higher than that in healthy people. More particularly, the inventor finds that high-level expression of DHFRL1 and/or TMEM87A has good sensitivity and specificity when being used for diagnosing prostatic cancer and is related to prognosis of prostatic cancer patients, so that DHFRL1 and/or TMEM87A can be used as a biomarker for diagnosis and prognosis judgment of prostatic cancer. 本发明涉及生物医药技术领域,特别是涉及一种用于前列腺癌诊断和预后判断的生物标志物及其应用。更具体地,本发明涉及一种用于前列腺癌的诊断和预后判断的生物标志物,所述生物标志物是DHFRL1和/或TMEM87A。本发明人已发现,DHFRL1和TMEM87A在前列腺癌患者中的表达水平明显高于健康人群中的表达水平。更特别地,本发明人发现,DHFRL1和/或TMEM87A的高水平表达在用于诊断前列腺癌时具有良</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PHYSICS</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZAh1yszPTSzKTi1SSMsvUkjJTEzPyy_OLFZIzEtRKCjKh_Ly00Cc4pLEklSF5MS8ZKBykILEgoKczOTEksz8PJCSJJhZPAysaYk5xam8UJqbQdHNNcTZQze1ID8-tbggMTk1L7Uk3tnP0NDczMjU3NLA0ZgYNQD1wTlu</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>ZHANG KAISHAN</creator><creator>HUANG CHENG</creator><creator>RAO LANGQING</creator><creator>YU LEI</creator><creator>MA NING</creator><creator>TIAN HUA</creator><scope>EVB</scope></search><sort><creationdate>20240301</creationdate><title>Biomarker for diagnosis and prognosis of prostate cancer and application of biomarker</title><author>ZHANG KAISHAN ; HUANG CHENG ; RAO LANGQING ; YU LEI ; MA NING ; TIAN HUA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN117625790A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PHYSICS</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHANG KAISHAN</creatorcontrib><creatorcontrib>HUANG CHENG</creatorcontrib><creatorcontrib>RAO LANGQING</creatorcontrib><creatorcontrib>YU LEI</creatorcontrib><creatorcontrib>MA NING</creatorcontrib><creatorcontrib>TIAN HUA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHANG KAISHAN</au><au>HUANG CHENG</au><au>RAO LANGQING</au><au>YU LEI</au><au>MA NING</au><au>TIAN HUA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Biomarker for diagnosis and prognosis of prostate cancer and application of biomarker</title><date>2024-03-01</date><risdate>2024</risdate><abstract>The invention relates to the technical field of biological medicine, in particular to a biomarker for diagnosis and prognosis of prostatic cancer and application of the biomarker. More specifically, the invention relates to a biomarker for diagnosis and prognosis of prostate cancer, and the biomarker is DHFRL1 and/or TMEM87A. The inventor has found that the expression level of DHFRL1 and TMEM87A in prostate cancer patients is obviously higher than that in healthy people. More particularly, the inventor finds that high-level expression of DHFRL1 and/or TMEM87A has good sensitivity and specificity when being used for diagnosing prostatic cancer and is related to prognosis of prostatic cancer patients, so that DHFRL1 and/or TMEM87A can be used as a biomarker for diagnosis and prognosis judgment of prostatic cancer. 本发明涉及生物医药技术领域,特别是涉及一种用于前列腺癌诊断和预后判断的生物标志物及其应用。更具体地,本发明涉及一种用于前列腺癌的诊断和预后判断的生物标志物,所述生物标志物是DHFRL1和/或TMEM87A。本发明人已发现,DHFRL1和TMEM87A在前列腺癌患者中的表达水平明显高于健康人群中的表达水平。更特别地,本发明人发现,DHFRL1和/或TMEM87A的高水平表达在用于诊断前列腺癌时具有良</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN117625790A
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
TESTING
VINEGAR
WINE
title Biomarker for diagnosis and prognosis of prostate cancer and application of biomarker
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A14%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHANG%20KAISHAN&rft.date=2024-03-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN117625790A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true